Kevzara and Pemphigus - a phase IV clinical study of FDA data

Summary:

Pemphigus is reported as a side effect among people who take Kevzara (sarilumab), especially for people who are female, 40-49 old, also take Cimzia, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Pemphigus when taking Kevzara. It is created by eHealthMe based on reports of 17,556 people who have side effects when taking Kevzara from the FDA, and is updated regularly.

What is Kevzara?

Kevzara has active ingredients of sarilumab. eHealthMe is studying from 17,561 Kevzara users. Check the latest studies of Kevzara.

What is Pemphigus?

Pemphigus (any of several acute or chronic skin diseases characterized by groups of itching blisters) is found to be associated with 305 drugs and 304 conditions by eHealthMe. Check the latest studies of Pemphigus.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

17,556 people reported to have side effects when taking Kevzara.
Among them, 2,496 people (14.22%) have Pemphigus.

Among these 2,496 people:

* Approximation only. Some reports may have incomplete information.

Do you take Kevzara and have Pemphigus?

- Check whether Pemphigus is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Kevzara:

Kevzara (17,561 reports)

Pemphigus treatments and more:

Pemphigus (15,307 reports)

How severe was Pemphigus and when was it recovered:

Pemphigus in Kevzara

Expand to all the drugs that have ingredients of sarilumab:

Pemphigus and drugs with ingredients of sarilumab

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Kevzara:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pemphigus:

Pemphigus (305 drugs)

Browse all the conditions that are associated with Pemphigus:

Pemphigus (304 conditions)

Related publications that referenced our studies

Dobrosavljevi? Vukojevi? D, Stojkovi? Filipovi? J, Sjerobabin M, Vukovi? J, Vesi? S, "Lisinopril-induced pemphigus foliaceus in a patient with diabetes mellitus and Kaposi-Juliusberg varicelliform eruption", Serbian Journal of Dermatology and Venerology, 2012 Dec .
Dobrosavljevi? Vukojevi? D, Stojkovi? Filipovi? J, Sjerobabin M, Vukovi? J, Vesi? S, "Lisinopril-induced pemphigus foliaceus in a patient with diabetes mellitus and Kaposi-Juliusberg varicelliform eruption", Serbian Journal of Dermatology and Venerology, 2012 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on sarilumab (the active ingredients of Kevzara) and Kevzara (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.